That's non GAAP "earnings". All revenue is deferred until FDA approval. I've been reading posts, not from sigaking, but others, that don't understand the associated accounting. Cash is received and a liability for deferred revenues recorded so that there will be no income from the provision of courses. So for GAAP purposes, SIGA should generate losses.
Once FDA approval occurs, SIGA will instantly recognize income for all deferred amounts. This is not an issue of accruing or not accruing, SIGA is on the accrual method obviously or it wouldn't be reporting under GAAP; it's a matter of deferral or not deferring the revenue associated with the receipt of cash for the provision of products.
The analysts understand the accounting, they will look at non GAAP results and cash flow.